Rapidly progressive rhino-orbito-cerebral mucormycosis in a patient with type 2 diabetes: A case report

Peleg AY, Weerarathna T, McCarthy JS and Davis TM: Common infections in diabetes: Pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 23:3–13. 2007. View Article : Google Scholar : PubMed/NCBI

Spellberg B, Edwards J Jr and Ibrahim A: Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev. 18:556–569. 2005. View Article : Google Scholar : PubMed/NCBI

Chinn RY and Diamond RD: Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: Relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun. 38:1123–1129. 1982.PubMed/NCBI

Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr and Spellberg BJ: The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 117:2649–2657. 2007. View Article : Google Scholar : PubMed/NCBI

Ibrahim AS: Host cell invasion in mucormycosis: Role of iron. Curr Opin Microbiol. 14:406–411. 2011. View Article : Google Scholar : PubMed/NCBI

Cagatay AA, Oncü SS, Calangu SS, Yildirmak TT, Ozsüt HH and Eraksoy HH: Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: A case report. BMC Infect Dis. 1:222001. View Article : Google Scholar : PubMed/NCBI

Ericsson M, Anniko M, Gustafsson H, Hjalt CA, Stenling R and Tärnvik A: A case of chronic progressive rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Clin Infect Dis. 16:585–586. 1993. View Article : Google Scholar : PubMed/NCBI

Pfaller MA, Messer SA, Hollis RJ and Jones RN: SENTRY Participants Group: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 46:1032–1037. 2002. View Article : Google Scholar : PubMed/NCBI

Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG and Graybill JR: In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 46:1581–1582. 2002. View Article : Google Scholar : PubMed/NCBI

Yoon YK, Kim MJ, Chung YG and Shin IY: Successful treatment of a case with rhino-orbital-cerebral mucormycosis by the combination of neurosurgical intervention and the sequential use of amphotericin B and posaconazole. J Korean Neurosurq Soc. 47:74–77. 2010. View Article : Google Scholar

Rybak JM, Marx KR, Nishimoto AT and Rogers PD: Isavuconazole: Pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 35:1037–1051. 2015. View Article : Google Scholar : PubMed/NCBI